Translational Neuroimaging Laboratory, McGill University Research Centre for Studies in Aging, Alzheimer's Disease Research Unit, Douglas Research Institute, Le Centre Intégré Universitaire de Santé et de Services Sociaux (CIUSSS) de l'Ouest-de-l'Île-de-Montréal, Montréal, Québec H4H 1R3, Canada; Department of Neurology and Neurosurgery, Faculty of Medicine, McGill University, Montreal, Quebec H3A 2B4, Canada.
Department of Psychiatry and Neurochemistry, Institute of Neuroscience and Physiology, The Sahlgrenska Academy, University of Gothenburg, Mölndal 6 431 41, Sweden; Wallenberg Centre for Molecular Medicine, University of Gothenburg, Gothenburg 6 431 41, Sweden; King's College London, Institute of Psychiatry, Psychology and Neuroscience, Maurice Wohl Institute Clinical Neuroscience Institute, London SE5 9RT, UK; NIHR Biomedical Research Centre for Mental Health and Biomedical Research Unit for Dementia at South London and Maudsley NHS Foundation, London SE5 8AF, UK.
EBioMedicine. 2024 Apr;102:105046. doi: 10.1016/j.ebiom.2024.105046. Epub 2024 Mar 11.
Blood-based biomarkers of Alzheimer's disease (AD) have become increasingly important as scalable tools for diagnosis and determining clinical trial eligibility. P-tau217 is the most promising due to its excellent sensitivity and specificity for AD-related pathological changes.
We compared the performance of two commercially available plasma p-tau217 assays (ALZpath p-tau217 and Janssen p-tau217+) in 294 individuals cross-sectionally. Correlations with amyloid PET and tau PET were assessed, and Receiver Operating Characteristic (ROC) analyses evaluated both p-tau217 assays for identifying AD pathology.
Both plasma p-tau217 assays were strongly associated with amyloid and tau PET. Furthermore, both plasma p-tau217 assays identified individuals with AD vs other neurodegenerative diseases (ALZpath AUC = 0.95; Janssen AUC = 0.96). Additionally, plasma p-tau217 concentrations rose with AD severity and their annual changes correlated with tau PET annual change.
Both p-tau217 assays had excellent diagnostic performance for AD. Our study supports the future clinical use of commercially-available assays for p-tau217.
This research is supported by the Weston Brain Institute, Canadian Institutes of Health Research (CIHR), Canadian Consortium on Neurodegeneration in Aging, the Alzheimer's Association, Brain Canada Foundation, the Fonds de Recherche du Québec - Santé and the Colin J. Adair Charitable Foundation.
作为诊断和确定临床试验资格的可扩展工具，基于血液的阿尔茨海默病（AD）生物标志物变得越来越重要。p-tau217 是最有前途的，因为它对 AD 相关病理变化具有出色的敏感性和特异性。
我们在 294 名个体中比较了两种市售的血浆 p-tau217 检测方法（ALZpath p-tau217 和 Janssen p-tau217+）的性能。评估了与淀粉样蛋白 PET 和 tau PET 的相关性，并通过接收者操作特征（ROC）分析评估了两种 p-tau217 检测方法识别 AD 病理的能力。
两种血浆 p-tau217 检测方法均与淀粉样蛋白和 tau PET 强烈相关。此外，两种血浆 p-tau217 检测方法均能识别 AD 与其他神经退行性疾病患者（ALZpath AUC=0.95；Janssen AUC=0.96）。此外，血浆 p-tau217 浓度随 AD 严重程度升高，其年度变化与 tau PET 年度变化相关。
两种 p-tau217 检测方法对 AD 均具有出色的诊断性能。我们的研究支持未来在临床中使用市售的 p-tau217 检测方法。
本研究由 Weston 脑研究所、加拿大卫生研究院（CIHR）、加拿大神经退行性变老化联盟、阿尔茨海默病协会、加拿大脑基金会、魁北克健康研究基金会和 Colin J. Adair 慈善基金会资助。
